After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
JNJ belongs to the Healthcare sector of the NYSE while operating in the Drug Manufacturers – General industry. At the end of the last regular session, the stock closed at $161.84 and fluctuated between $162.25 as its day high and $160.16 as its day low. The current market capitalization of Johnson & Johnson is $389.84B. A total of 6.6 million shares were traded on the day, compared to an average of 7.27M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, JNJ has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 10 SELLs from insiders. Insiders purchased 14,698 shares during that period but sold 63,097.
In the most recent transaction, Taubert Jennifer L sold 59,397 shares of JNJ for 156.27 per share on Feb 09. After the transaction, the EVP, WW Chair, Pharmaceuticals now owns 141,416 company shares. In a previous transaction on Jul 26, Hait William sold 14,698 shares at 172.00 per share. JNJ shares that the insider owns now total 87,747.
Among the insiders who sold shares, Fasolo Peter disposed of 20,000 shares on Jul 25 at a per-share price of $170.32. This resulted in the Exec VP, Chief HR Officer holding 102,696 shares of JNJ after the transaction. In another insider transaction, Wengel Kathryn E sold 12,465 shares at $160.00 per share on Jun 12. Company shares held by the EVP, Chief TO and Risk Officer now total 65,934.
Dividend
Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Johnson & Johnson pays an annual dividend of $4.76, resulting in a dividend yield of 2.94%, and it has a price to earnings (P/E) ratio of 29.02. JNJ’s most recent ex-dividend date was 2/16/2024 when it declared a $1.19 quarterly dividend that was paid in cash on 3/5/2024. Previously, the company paid the dividend on 12/5/2023 with an ex-dividend date of 11/20/2023. The JNJ stock dividend was $1.19 per share in cash.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for JNJ in the last 3 months, the mean price target is $176.28 with high estimates of $215.00 and low estimates of $160.00. In terms of 52-week highs and lows, JNJ has a high of $175.97 and a low of $144.95.
As of this writing, JNJ has an earnings estimate of $2.63 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of $2.77 per share and a lower estimate of $2.44. The company reported an EPS of $2.66 in the last quarter, which was 5.60% higher than expectations of $2.52.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. JNJ’s latest balance sheet shows that the firm has $31.61B in Cash & Short Term Investments as of fiscal 2021. There were $33.75B in debt and $45.23B in liabilities at the time. Its Book Value Per Share was $28.57, while its Total Shareholder’s Equity was $74.02B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for JNJ is Buy with a score of 3.90.
